|
REFERENCES 1. Lewis JH, Mortensen ME, Zweig S, Fusco MJ, Medoff JR, Belder R. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology 2007;46(5):1453-63. 2. Bjornsson E JE, Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. Journal of hepatology 2012;56(2):374-80. 3. http://www.fda.gov/Drugs/DrugSafety/ucm293101.htm (Accessed on February 28. February 28, 2012. 4. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial. The Lancet 2002;360(9326):7-22. 5. Charles EC, Olson KL, Sandhoff BG, McClure DL, Merenich JA. Evaluation of cases of severe statin-related transaminitis within a large health maintenance organization. The American journal of medicine 2005;118(6):618-24. 6. Tsan YT, Lee CH, Wang JD, Chen PC. Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(6):623-30. 7. Lai MN, Wang SM, Chen PC, Chen YY, Wang JD. Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk. Journal of the National Cancer Institute 2010;102(3):179-86. 8. WHO Collaborating Center for Drugs Statis-tics Methodology: ATC Index with DDDs 2003.Oslo N, WHO, 2003. 9. Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. The New England journal of medicine 2012;367(19):1792-802. 10. Lee CH, Wang JD, Chen PC. Increased risk of hospitalization for acute hepatitis in patients with previous exposure to NSAIDs. Pharmacoepidemiology and drug safety 2010;19(7):708-14. 11. Brewer HB. benefit-risk assessment of Rosuvastatin 10 to 40 milligrams. The American journal of cardiology 2003;92(4):23-29. 12. Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study. Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2005;19(6):403-14. 13. Goh IX, How CH, Tavintharan S. Cytochrome P450 drug interactions with statin therapy. Singapore Med J 2013;54(3):131-5. 14. Lee CH, Wang JD, Chen PC. Case-crossover study of hospitalization for acute hepatitis in Chinese herb users. Journal of gastroenterology and hepatology 2008;23(10):1549-55. 15. Armitage J. The safety of statins in clinical practice. Lancet 2007;370(9601):1781-90. 16. Kashani A, Phillips CO, Foody JM, Wang Y, Mangalmurti S, Ko DT, et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 2006;114(25):2788-97. 17. Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002;36(2):451-5. 18. Rosenson RS. Current overview of statin-induced myopathy. The American journal of medicine 2004;116(6):408-16. 19. Smith CC, Bernstein LI, Davis RB, Rind DM, Shmerling RH. Screening for statin-related toxicity: the yield of transaminase and creatine kinase measurements in a primary care setting. Archives of internal medicine 2003;163(6):688-92. 20. Zhang H, Plutzky J, Turchin A. Discontinuation of statins in routine care settings. Annals of internal medicine 2013;159(1):75-6. 21. Zhang H, Plutzky J, Skentzos S, Morrison F, Mar P, Shubina M, et al. Discontinuation of statins in routine care settings: a cohort study. Annals of internal medicine 2013;158(7):526-34. 22. Bernal W, Auzinger G, Dhawan A, Wendon J. Acute liver failure. Lancet 2010;376(9736):190-201.
|